Astrazeneca plc
Open
$178.92
Prev. Close
$179.01
High
$179.14
Low
$178.56
Market Snapshot
$277.22B
26.7
4.54
$54.07B
AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. The firm focuses on the discovery, development, and commercialization of prescription medicines. The firm operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. The company has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The firm distributes its products in over 125 countries.
AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. The firm focuses on the discovery, development, and commercialization of prescription medicines. The firm operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. The company has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The firm distributes its products in over 125 countries.
Recently from Cashu
AstraZeneca Partners with LCRF to Advance Small Cell Lung Cancer Research Grants
AstraZeneca plc (Ticker: AZN) actively partners with the Lung Cancer Research Foundation (LCRF) to enhance treatment outcomes for patients suffering from small cell lung cancer (SCLC). On June 9, 2026…
AstraZeneca and LCRF Launch Initiative to Advance Small Cell Lung Cancer Research and Treatment
AstraZeneca plc (Ticker: AZN) collaborates with the Lung Cancer Research Foundation to address the urgent need for innovative treatments for small cell lung cancer (SCLC). The joint initiative announc…
AstraZeneca’s eneboparatide shows significant promise in treating chronic hypoparathyroidism in CALYPSO trial.
AstraZeneca plc (Ticker: AZN) announces promising results from its Phase 3 CALYPSO trial for eneboparatide, a treatment targeting chronic hypoparathyroidism. The trial reveals that 31.1% of patients o…
AstraZeneca's Truqap Receives FDA Advisory Panel's Strong Support for Prostate Cancer Treatment.
AstraZeneca achieves a significant milestone with its prostate cancer drug Truqap (capivasertib). A recent FDA advisory panel votes 7-1, with one abstention, to recognize its favorable benefit-risk pr…